共 46 条
- [21] Pharmacokinetics/pharmacodynamics of Sandoz biosimilar pegfilgrastim compared to both US- and EU-reference pegfilgrastim: A meta-analysis of three clinical studies in healthy subjectsCANCER RESEARCH, 2020, 80 (04)Nakov, RoumenWang, JessieBellon, AnneGattu, SreekanthArani, Ramin
- [22] A large multicenter, randomized, double-blind, crossover study in healthy volunteers, comparing pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar pegfilgrastim with European and United States reference pegfilgrastim.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Otto, Gordon P.Nakov, RoumenSchussler, StevenSchier-Mumzhiu, StefanieSchelcher, CelineKoch, Sven D.Skerjanec, AndrejWang, JessieKrendyukov, AndriyBellon, Anne
- [23] Pharmacokinetics and pharmacodynamics of proposed denosumab biosimilar and reference denosumab in healthy male subjectsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Vogg, BarbaraPoetzl, JohannEl Galta, RachidFuhr, RainardSchwebig, ArndSekhar, Susmit
- [24] A large multi-center, randomized, double-blind, crossover study in healthy volunteers to compare pharmacokinetics and pharmacodynamics of a proposed biosimilar pegfilgrastim with EU and US reference pegfilgrastim: Methodological approachANNALS OF ONCOLOGY, 2018, 29 : 637 - 637Nakov, R.Schussler, S.Schier-Mumzhiu, S.Skerjanec, A.Bellon, A.Wang, J.Krendyukov, A.Otto, G.
- [25] Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(R) in healthy subjects: A randomized, double-blind trialPHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (02):Wynne, ChrisSchwabe, ChristianVincent, EmmanuelleSchueler, ArminRyding, JankaUllmann, MartinGhori, VishalKanceva, RadmilaStahl, Michael
- [26] PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta®): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy VolunteersAdvances in Therapy, 2020, 37 : 3370 - 3391Shahrzad MoosaviTroy BoremaReginald EwesuedoStuart HarrisJeffrey LevyThomas B. MayMartin SummersJeffrey S. ThomasJeffrey ZhangHsuan-Ming Yao
- [27] PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta(R)): Pharmacodynamics, Pharmacokinetics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy VolunteersADVANCES IN THERAPY, 2020, 37 (07) : 3370 - 3391Moosavi, ShahrzadBorema, TroyEwesuedo, ReginaldHarris, StuartLevy, JeffreyMay, Thomas B.Summers, MartinThomas, Jeffrey S.Zhang, JeffreyYao, Hsuan-Ming
- [28] PROPOSED PEGIFLGRASTIM BIOSIMILAR CHS-1701 DEMONSTRATES PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY TO MARKETED PEGFILGRASTIM IN A RAT NEUTROPENIA MODEL AND IN HEALTHY SUBJECTSHAEMATOLOGICA, 2017, 102 : 471 - 471O'Connor, P.Tang, H.Civoli, F.Finck, B.Vexler, V.
- [29] A pharmacokinetics and pharmacodynamics equivalence trial of proposed pegfilgrastim biosimilar, MYL-1401H vs EU neulasta® and US neulasta®ANNALS OF ONCOLOGY, 2016, 27Waller, C. F.Tiessen, R.Lawrence, T.Shaw, A.Liu, M.Sharma, R.Baczkowski, M.Kothekar, M.Dias, R.Barve, A.Pennella, E.
- [30] A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind TrialONCOLOGIST, 2016, 21 (07): : 789 - 794Blackwell, KimberlyDonskih, RomanJones, C. MichaelNixon, AllenVidal, Maria J.Nakov, RoumenSingh, PritibhaSchaffar, GregorGascon, PereHarbeck, Nadia